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Abstract
Background: Picropodophyllin (PPP) is a promising novel anti-neoplastic agent that efficiently kills tumor cells in vitro and
causes tumor regression and increased survival in vivo. We have previously reported that PPP treatment induced moderate
tolerance in two out of 10 cell lines only, and here report the acquired genomic and expression alterations associated with
PPP selection over 1.5 years of treatment.
Methodology/Principal Findings: Copy number alterations monitored using metaphase and array-based comparative
genomic hybridization analyses revealed largely overlapping alterations in parental and maximally tolerant cells. Gain/
amplification of the MYC and PVT1 loci in 8q24.21 were verified on the chromosome level. Abnormalities observed in
connection to PPP treatment included regular gains and losses, as well as homozygous losses in 10q24.1-q24.2 and 12p12.3-
p13.2 in one of the lines and amplification at 5q11.2 in the other. Abnormalities observed in both tolerant derivatives
include amplification/gain of 5q11.2, gain of 11q12.1-q14.3 and gain of 13q33.3-qter. Using Nexus software analysis we
combined the array-CGH data with data from gene expression profilings and identified genes that were altered in both
inputs. A subset of genes identified as downregulated (ALDH1A3, ANXA1, TLR4 and RAB5A) or upregulated (COX6A1, NFIX,
ME1, MAPK and TAP2) were validated by siRNA in the tolerant or parental cells to alter sensitivity to PPP and confirmed to
alter sensitivity to PPP in further cell lines.
Conclusions: Long-term PPP selection lead to altered gene expression in PPP tolerant cells with increase as well as decrease
of genes involved in cell death such as PTEN and BCL2. In addition, acquired genomic copy number alterations were
observed that were often reflected by altered mRNA expression levels for genes in the same regions.
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Introduction
Resistance to cancer treatment is a major cause of disease
recurrence and mortality in modern oncology. On the functional
level, drug resistance may affect processes such as uptake and
processing of the drug, modifications of the target and induction of
DNA repair [1]. Alterations related to the cell cycle, programmed
cell death and escape of apoptosis are other important factors in
therapy resistance. Underlying molecular alterations can be found
at the DNA level, e.g. copy number variation and sequence
mutation, at the transcriptional level e.g. regulatory or posttran-
scriptional changes or involve translational or posttranslational
modification of proteins. Epigenetic modifications have also been
shown to affect drug sensitivity and resistance. These include e.g.
altered methylation of individual gene promoters [2,3,4] or
genome-wide changes [5], as well as alterations in expression of
microRNAs [6].
The cyclolignan picropodophyllin (PPP) is a promising anti-
cancer agent with documented tumor inhibitory effects. In
experimental systems, PPP causes massive apoptosis of malignant
cells, reduced cell motility in vitro and in vivo tumor regression was
observed not only in xenografted mice and mouse tumor models
[7-13] but also in intracerebral rat xenografts [14]. Furthermore,
PPP at therapeutically achievable doses prolonged survival by up
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drug was well tolerated by the animals and in addition to the
reduction of tumor burden, decreased tumor-associated angio-
genesis and osteolysis were observed [9,15,16]. PPP has been
reported to cause ubiquitination of the insulin like-growth factor 1
receptor (IGF-1R) and thereby inhibit its activation, which caused
attenuation of the phosphatidyl-3 inositol (PI3K) anti-apoptotic
pathway [7,8,12,13,17-19]. However, PPP did not inhibit the
highly homologous insulin receptor, thereby circumventing the
risk for diabetogenic responses associated with many other anti-
IGF-1R therapies. An oral IGF-1R inhibitor (AXL1717) of
cyclolignan chemistry is presently studied in cancer patients (phase
I/II) with successful results (www.axelar.se).
Our previous selection experiments on cultured tumor cells
failed to produce resistance to PPP [7]. PPP treatment produced
only weak tolerance in two out of ten tumor cell lines selected for
increasing doses of PPP over an 80-week period [7]. Moreover, the
multidrug resistance proteins MDR1 and MRP1 were not found
to be affected by long-term PPP treatment [7], consistent with
another study showing that PPP effectively killed multidrug
resistant osteosarcoma cells [12].
Even though in vitro studies have suggested low incidence for
PPP resistance, it is important to explore the potential genetic
mechanisms underlying tolerance to PPP, not least from a clinical
perspective as these types of compounds may in future be used in
treatment of human cancer. In this context we have here evaluated
genome-wide gene expression patterns and copy number genomic
alterations in association with in vitro long term PPP treatment in
human cancer cells.
Materials and Methods
Cell lines and culturing
The generation of PPP tolerant derivatives from the established
human cancer cell lines Line2 and Line3 have been previously
reported [7]. The parental cell line Line2, corresponding to DFB
melanoma cells originally named DFBmel [20], was kindly
provided by Prof. Rolf Kiessling at Karolinska Institutet, and
Line3, ES1 Ewing sarcoma cells, was obtained from American
Type Culture Collection (Rockville, MD) [8]. The parental cell
lines were selected by incubation in increasing concentrations of
PPP as described in [7]. The IGF-1R expression, IGF-1R
dependency and PPP responsiveness of the parental cells has
been previously reported [7]. To generate PPP tolerant deriva-
tives, Line2 and Line3 cells were exposed to increasing doses of
PPP from 10 to 500 nM over an 80-week period resulting in
derivatives with different levels of PPP tolerance, as previously
reported [7]. As paired control cell lines, the parental untreated
cells were cultured in parallel for 80 weeks. The suffix 500 and 200
in Line2-T500 and Line3-T200 refers to the highest levels of PPP
tolerance obtained, in nM. The parental and tolerant cells used in
the present study were stored at 2135
uC, thawed and cultured for
30 days in the absence or presence of PPP at the same
concentration as the highest observed tolerance.
The BE melanoma cell line was a kind gift from Prof. Rolf
Kiessling at Karolinska Institutet, and MCF7 breast cancer was
obtained from American Type Culture Collection (Rockville, MD)
[8]. BE and MCF cell lines are PPP non-tolerant and were used as
controls in siRNA and cell viability experiments.
DNA extraction
Genomic DNA was isolated from cultured cells according to
standard procedures applying either phenol/ chloroform purifi-
cation and ethanol precipitation, or using a commercial kit
(QiagenGmbh, Hilden, Germany). DNA samples were subse-
quently used for genotyping, metaphase comparative genomic
hybridisation (CGH), array-CGH and methylation analysis.
Genotyping of parental and PPP tolerant cells
Short tandem repeat (STR) profiling was performed on all cell
lines assayed by metaphase-CGH using the AmpFlSTR Profiler
Plus
TM PCR amplification kit and an ABI 377 DNA sequencer
(Applied Biosystems, Foster City, CA, USA). The markers
included D3S1358, FGA, D5S818, D7S820, D8S1179, vWA,
D13S317, D18S851, D21S11 and Amelogenin. Parental and PPP
treated Line2 cell lines at all tolerance levels tested (40, 100, 300
and 400 nM) were characterized by the genotypes 15; 20; 11/12;
9/11; 11/13; 16/17; 11/12; 15; 28/31; and X/Y. Parental and
PPP treated Line3 cells (40 and 100nMand 200 nM at two
different time-points) showed the genotypes 15; 24; 13; 8/9; 13/
14; 16; 12; 13; 30; and X.
In addition, genotyping of single nucleotide polymorphism
(SNP) was carried out at the Mutational Analysis Facility (MAF),
Karolinska Institutet, Stockholm, for all lines analysed by array-
CGH using the marker panel and analysis system introduced by
Hannelius et al [21]. In total, 47 SNPs were genotyped using a
Sequenom
TM mass spectrometer and results were compared pair-
wise between parental and maximally tolerant cell lines.
Spectral karyotyping (SKY)
SKY analysis was performed as described [22] on metaphase
spreads of parental Line2 and Line3 cells. Image acquisitions were
performed using a SD200 Spectracube system (ASI) mounted on a
Zeiss Axioskop microscope (Carl Zeiss Jena GmbH, Jena,
Germany) with a custom-designed optical filter (SKY-1, Chroma
Technology, Brattleboro, VT, USA). Karyotypes were based on
analyses of 7 and 10 complete chromosome spreads for Line2 and
Line3, respectively. Descriptions of karyotypes follow the recom-
mendations of the International System for Human Cytogenetic
Nomenclature (ISCN 1995) [23].
Metaphase-CGH
CGH was performed on parental and PPP tolerant Line2 cells
(40, 100, 300, 400 and 500 nM)and Line3 cells (40 and100 nM and
200 nM PPP at two different time-points) using methods previously
described [24]. DNA was extracted from ,6.0610
6cells in
monolayer cultures. In brief, 1 mg cell line DNA (test) was labelled
with FITC (green, NEN Life Science, Boston MA, USA) and the
normal DNA (reference) with Spectrum Red (red, Vysis, Inc.),
mixed with human COT-1 DNA (Invitrogen) and hybridized
together onto denatured metaphase spreads from normal male
lymphocytes (Vysis, Inc.). Images were captured with a Zeiss
Axioplan 2 and analyzedwith the Isis/CGH software(Metasystems,
Germany). Based on green-to-red ratios, copy number alterations
were classified as losses (ratios#0.8), gains ($1.2) or amplifications
($1.5). Heterochromatic regions, the short arms of the acrocentric
chromosomes and chromosomes X and Y were excluded and GC
rich regions in 1p, 19 and 22 were interpreted with caution. As
controls, normal male DNA was hybridized against normal female
DNA and cell lines were hybridized and analyzed on two separate
occasions.
Array-CGH
Array-CGH was performed on parental and tolerant cells at the
maximum tolerated PPP level including Line2, Line2-T500, Line3
and Line3-T200. Generation of microarrays, experimental
procedures and data analyses have previously been described in
Mechanisms of PPP Tolerence
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BAC clone library (CHORI BACPAC resources, (http://bacpac.
chori.org/genomicRearray.php) at the SCIBLU Genomics Cen-
tre, Lund University, Sweden (www.lu.se/sciblu) providing a
resolution of one clone per 50–100 kb.
One microgram of cell-line test DNA and normal reference
DNA (Promega, USA) were labelled separately with Cy3-dCTP
and Cy5-dCTP (PA53021, PA55021; GE Healthcare) using a
random labelling kit (BioPrime Array CGH Genomic kit;
Invitrogen Life Technologies, Carlsbad, CA, USA), purified with
a Purelink PCR purification kit (Invitrogen Life Technologies,
Carlsbad, CA, USA) and co-precipitated with human COT-1
DNA (Invitrogen). DNA probes were subsequently resuspended in
50 ml of formamide-based hybridization solution, denatured and
hybridized to arrays in chambers (Corning Inc, Corning, NY) for
72 h at 37
uC. After hybridization and stringent washing (50%
formamide/26SSC at 45
uC for 20 min, 26SSC/0.1% SDS at 45
uC for 30 min and 0.26SSC at room temperature for 15 min),
slides were dried by nitrogen blowing and scanned using a
Genepix 4200A confocal scanner (Axon instruments Inc., Union
City, CA).
Images were quantified using the GenePix Pro 6.0 package
analysis software (Axon instruments, Wheatherford TX, USA) and
uploaded at the BioArray Software Environment (BASE; http://
www.base.thep.lu.se/) [26] for filtering, normalization and
statistical analysis, as described in [27]. First, spots flagged by
the GenePix software or disqualified after manual inspection were
removed. Subsequently, probes with spot diameter ,40 mmo r
intensity below background were removed. Background-corrected
data was obtained by calculating the median foreground and
subtracting the median background signal intensity for each
channel. Intensity ratios for individual probes were calculated
within arrays from background-corrected intensity levels of test
sample divided by reference sample and data were normalized
using the pin-based LOWESS algorithm [28]. The data was
smoothed using a three-clone sliding window and CGH plotter
[29] was used to identify the extent of alterations using a
segmentation constant of 7. Log2 ratios for two continuous BAC
clones outside the threshold ranges were classified as copy number
changes including gain (threshold +0.25), loss (20.25), amplifica-
tion (+1) and homozygous loss (21). Small aberrations in the
telomeric regions were not taken into account due to chromosomal
instability in these regions.
Information about physical and cytogenetic locations of clones
was according to the UCSC genome browser (http:/www.genome.
ucsc.edu/; July 2004 freeze). Our findings from the 33k array were
compared with a previous analysis using a commercially available
1 Mb resolution array (Spectral Genomics, Houston, TX USA)
and showed concordant results (data not shown).
Fluorescence in situ hybridization (FISH)
FISH analysis was performed on Line2, Line2-T500, Line3 and
Line3-T200 cells using a commercially available Spectrum
Orange labelled probe for the MYC locus at 8q24.21 (Vysis LSI
C-MYC Abbott Molecular, Illinois, USA). The results were
analyzed in a Zeiss Axioplan 2 epifluorescence microscope (Carl
Zeiss Jena GmbH, Jena, Germany) and documented using a
SD200 Spectracube system (ASI). For each cell line, between 30
and 60 interphase nuclei were scored for the number of MYC
signals with additional evaluation of 2–5 metaphases.
Gene expression profiling
RNA was prepared from Line2, Line2-T500, Line3, and Line3-
T200 cells using the RNeasy miniprep kit (Qiagen, Chatsworth,
CA) and used for expression analysis, which was carried out at the
Uppsala Array Platform. Gene expression profiling was performed
using the Genome U133 Plus 2.0 arrays with methodology as
recommended in the GeneChip Expression Analysis Technical
Manual (Rev. 5, Affymetrix Inc., Santa Clara, CA). Raw data was
processed by MAS5 in the Affymetrix GeneChip Operating
Software (GCOS) to generate quantitative signals and qualitative
Detection Calls.
Integration of array-CGH and expression data by Nexus
The array-CGH data was processed in the Nexus 3.1
(BioDiscovery Inc., El Segundo, CA, USA) software using the
built-in Rank segmentation algorithm to identify regions of relative
copy-number alterations in Line2-T500 vs. Line2 and Line3-T200
vs. Line3 cells. The following parameters that were different from
default were applied: p=1610
26, a minimum of 5 probes, and
60.2 as a threshold for gain or loss. The identified regions were
subsequently integrated with corresponding Affymetrix expression
data, with separate analyses of alterations in Line2-T500, Line3-
T200, and Line2-T500 and Line3-T200 combined.
Identification of dysregulated genes in tolerant lines and
functional annotations
Differentially expressed genes between Line2-T500 vs. Line2
and Line3-T200 vs. Line3 cells were identified using two different
criteria. Gene list U was generated by MAS5 including genes with
.2-fold difference between parental and PPP treated cells and
giving a ‘‘present’’ detection flag in both cell lines (Uppsala Array
Platform).
For gene list H, more stringent criteria were used (at core facility
BEA, Huddinge, Karolinska Institutet). This time probes were
selected based on the following criteria i) increased or decreased
call (significant difference in expression), ii) minimum of a two-fold
change in expression levels (Signal Log Ratio (SLR)$1 and
SLR#21 respectively) and iii) Present Call in the samples. The
193 probe sets from gene list H identified as commonly
dysregulated in both lines (78 up-regulated and 115 down-
regulated) were entered into hierarchical clustering using the R
software programme (http://www.r-project.org/). Functional
annotation was performed for gene list U and H using the
database for annotation, visualization and integrated discovery
(DAVID) (http://david.abcc.ncifcrf.gov/) [30]. Functional classi-
fication categories with enrichment scores $1and p-values ,0.05
were studied in more detail.
Treatment with siRNA and assessment of cell viability
Gene specific Silencer Select siRNA (Ambion) against six genes
downregulated in PPP tolerant cell lines (ALDH1A3, ANXA1,
TLR4, SPIN3, SOCS3 and RAB5A) were transfected into non-
tolerant Line2, Line3, BE and MCF7 cells. Silencer Select siRNA
against seven genes upregulated in PPP tolerant cell lines
(COX6A1, LGALS2, NFIX, ME1, BCL2, MAPK and TAP2) were
transfected into Line2-T500, Line3-T200 PPP tolerant and non-
tolerant, BE and MCF7 cells. Sequences for siRNA are available
on request.
Transfection of siRNA was performed with Lipofectamine
RNAiMAX (Invitrogen) at a ratio of 10 pmol siRNA to 0.6 ml
RNAiMAX. A reverse transfection mixture using 6 pmol siRNA
per well was plated into wells of a 96 well plate and 5,000 cells/
well added. Untransfected cells, RNAiMAX only and negative
siRNA controls were included for each cell line. The cells were
incubated for 24 h and the medium changed to 100 ml fresh
medium with and without 0.5 mM PPP. After a further 48 h, 10 ml
Mechanisms of PPP Tolerence
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cells incubated for 4 h at 37 uC and the fluorescence emission at
585 nm measured (Tecan Infinite M1000). It was confirmed that
the fluorescence measurements were within the range for which
they correlate linearly with cell number. The sensitivity to PPP was
assessed by calculating the ratio between the cell viability
measurement of siRNA treated cells with and without PPP
treatment, to normalize for effect on cell viability of the siRNA
transfection procedure. For the sensitivity curves, Line2 untrans-
fected and transfected with ALDH1A3 or ANXA1siRNA and
Line2-T500 untransfected or transfected with COX6A1 and NFIX
siRNA in 96 well plates were incubated after 24 h with 0, 0.05,
0.5, 1 and 2.5 mM PPP for 48 h and cell viability measured with
alamarBlue.
qRT-PCR to confirm effect of siRNA on gene expression
Line2 and Line2-T500 were transfected with siRNA using
Lipofectamine RNAiMAX in the same ratios as for the functional
experiments except in 6 well plates and after 36 hours, the RNA
extracted using the GeneJET RNA purification kit (Fermentas)
according to the manufacturer’s instructions. RNA concentration
was determined by NanoDrop spectrophotometer and 1 mg was
incubated in 16DNase buffer with 1 U of DNase I for 30 mins at
37 uC in a total volume of 10 ml. The solution was brought to
5 mM EDTA and heated to 65 uC for 10 mins to inactivate the
enzyme. RTase buffer, 0.5 mg oligo dT primer, 1 mM dNTPs and
200 U of RevertAid reverse transcriptase (Fermentas) were added
to the DNase treated RNA to a total volume of 20 ml and reverse
transcribed into cDNA through incubation at 50 uC for 30 mins
followed by enzyme inactivation at 85 uC for 5 mins. Primers for
quantitative real-time reverse transcription polymerase chain
reaction (qRT-PCR) were designed using the Primer 3 pro-
gramme (http://frodo.wi.mit.edu/primer3/) and were synthesised
by Sigma Aldrich (Table S1). Primers were dissolved in TE buffer
at 100 mM and then diluted to a working concentration of 20 mM
with water. The PCR reaction mixture consisted of 16Maxima
SYBR Green/ROX qPCR Master Mix (Fermentas), 1 ml cDNA
and 0.3 mM of both forward and reverse primers in a total volume
of 10 ml. Ten fold serial dilutions of cDNA from the untreated cell
lines, from 1 to 1:100, was analysed and used to construct a
standard curve for each gene. For each primer pair a negative
control PCR reaction was performed that did not contain cDNA
template. The qRT-PCR reactions were assembled in MicroAmp
384 well optical reaction plates (Applied Biosciences). Each gene
and cDNA combination was analysed in triplicate. The plates
were sealed with a lid and centrifuged for 1 min at 5,000 rpm. The
reaction plates were placed in an ABI Prism 7900HT sequence
detection system (Applied Biosystems) and heated to 50 uC for 2
min, 95 uC for 10 min to activate the polymerase and denature the
primers followed by 40 cycles of 60 uC for 1 min annealing,
extension occurring during increase to 95 uC and 95 uC for 15 s
denaturation. Fluorescence was measured and data collected at 95
uC and 60 uC during each cycle. Following completion of the
amplification, products were denatured by heating from 60 uCt o
95 uC, during which data was collected to produce dissociation
curves. The data was analysed by the SDS 2.3 programme. The
threshold was automatically selected at a point where the increase
in fluorescence was exponential. The SDS 2.3 produces a standard
curve for each pair of primers and calculates the quantity for each
unknown sample from the line of best fit from the standard curve
and calculates the quantity mean for the 3 well replicates. It was
confirmed that the dissociation curves showed a single peak at the
correct melting temperature for the primer pair (Table S1). The
quantity mean for each test gene was divided by the GAPDH
quantity mean for that sample to adjust for the amount of cDNA
present.
Luminometric methylation assay (LUMA)
Genome-wide DNA methylation at CCGG sites was deter-
mined by LUMA in the parental Line2 and Line3 and PPP
tolerant Line2-T500 and Line3-T200 cells. For methylation assay,
the parental Line2 and tolerant Line2-T500 cells were cultured for
24 h with 500 nM PPP (total PPP for tolerant Line2-T500 was
1000 nM). The PPP dose for parental Line3 and tolerant Line3-
T200 was 200 nM (total PPP for Line3-T200 was 400 nM).
The LUMA methodology has been described in detail
elsewhere [31]. In short, each cell line DNA sample was digested
with HpaII and EcoR1 or MspI and EcoR1 followed by cleavage
quantification using Pyrosequencing in a PSQ96 MA system
(Biotage AB, Uppsala, Sweden). Peak heights were determined
with the PSQ MA software for calculation of HpaII/MspI ratios
(HpaII/EcoR1)/(MspI/EcoR1). A HpaII/MspI ratio approaching
one indicates 0% methylation while a ratio approaching zero
suggest 100% methylation. All experiments were performed twice
on separate occasions.
Results
Genotyping of parental and PPP tolerant cell lines
STR profiling demonstrated identical genotypes between the
parental Line2 and the treated Line2 cell lines at the different
levels of tolerance, as well as between Line3 and the tolerant Line3
cell lines. High concordance in SNP genotypes was also observed
between Line2 and Line2-T500 (91%), and between Line3 and
Line3-T200 (91%).
Characterization of parental cell lines by SKY
The chromosomal compositions of parental Line2 and Line3
cells were characterized by SKY (Figure S1). Line2 displayed a
hypertriploid chromosome content and Line3 was found to be
hyperdiploid. Although most of the breakpoints observed in Line2
and Line3 were clearly different, some commonly involved regions
could be identified. Specifically, regions 2p22, 5q21, and 21p11
that contain known fragile sites, were found rearranged in both
lines, however each involved different translocation partners
(Figure S1). The results were in agreement with our previous
exclusion of gross rearrangement at the IGF1R locus in 15q26.3
using FISH analyses with flanking genomic clones [7].
Metaphase CGH abnormalities during PPP treatment
The chromosomal gains and losses identified by metaphase
CGH in parental and tolerant cell lines are illustrated in Figure S2.
Gains, losses and amplifications involving a subset of chromosomes
were identified in all parental and tolerant cell lines. Amplifica-
tions were identified in chromosomal regions 3p11-p14 and 7q32-
qter in parental and PPP treated Line2. Alterations of chromo-
some 11 were observed as the only common aberrations. Losses
involving 11q23-qter were detected in parental and PPP treated
Line2 at 40 nM and higher concentrations and gains in 11p12-q13
were acquired in Line2-T100 and cell lines tolerant to higher
concentrations of PPP. Furthermore, while Line3 cells did not
exhibit alterations of chromosome 11, gain of 11p12-q13 and loss
of 11q23-qter both occurred from Line3-T100 onwards. Thus,
common to both cell lines were gains in 11p12-q13 that appeared
at 100 nM and persisted until the end of study. Other alterations
observed in PPP treated cell lines include gain of 13q22-qter and
17p11.2-p12 in Line3 T (Figure S2).
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verification by FISH
Array-CGH was performed on parental and maximally PPP
tolerant cell lines of Line2 and Line3 using tiling BAC arrays.
Copy number alterations related to PPP treatment were identified
by comparison between abnormalities in parental and PPP
tolerant cell lines. These changes are of interest since they may
represent resistance mechanisms. In addition to the scoring of
copy number alterations using CGH plotter, log2 ratio profiles
were compared manually between parental and tolerant cell lines,
which identified a few distinct alterations with ratios at but not
outside the thresholds, and these were considered as borderline
alterations. Furthermore, given that PPP tolerance could only be
achieved in a minority of cell lines, abnormalities present in
parental cell lines were also considered as possibly contributing to
the PPP resistance.
The detected copy-number abnormalities are detailed for
each cell line in Tables S2 and S3. Almost all chromosomes
were affected in both parental and tolerant cell lines. In
addition to regular gains and losses, amplifications and
homozygous losses were also observed (Tables S2 and S3).
Among these can be noted the homozygous loss including the
CDKN2A locus at 9p21.3 in Line2 and Line2-T500. Copy
number gains or amplifications involving 8q24.21 were detected
in all lines (Figure 1) and were verified by locus specific FISH
analysis for the MYC locus (Figure 1). At array-CGH Line2 and
Line2-T500 revealed similar gains of 8q24.13-qter. FISH
analyses detected mean signal numbers of 3.5 (range 2–6;
n=56) in Line2 and of 3.4 (2–6; n=57) in Line2-T500, with
single signals observed on different chromosomes in metaphase.
In Line3 and Line3-T200 cell lines, array-CGH showed narrow
amplifications at 8q24.21. In these lines FISH analyses showed
mean numbers of 7.2 (range 4–12; n=31) in Line3 and of 5.1
(3–10; n=42) in Line3-T200, and in metaphases the majority of
signals were found clustered on one chromosome suggesting a
small homogenously staining region (HSR, Figure 1). Detailed
analysis of the gained interval in 8q24.21 showed that MYC and
PVT1 were both gained or amplified in parental and PPP
tolerant cell lines.
Parental and PPP tolerant cell lines were identical in the
majority of copy number aberrations detected. Consequently, only
a limited number of acquired gains and losses in relation to PPP
tolerance were identified (Table 1). In addition, some alterations
identified in parental cell lines were not retained in the tolerant
derivatives (Table S1). Alterations of larger chromosome segments
were found in tolerant cells including losses (5p, 6, 9, 12p and 21q)
and gains (5q, 10, 11, 12p, 13q and 18q) in Line2-T500, as well as
losses (3p, 7q, 11q, 16q and 17q) and gains (1q, 3q, 4p, 5p, 8q, 11,
17q, 18q and 22q) in Line3-T200 (Table 1). Homozygous losses
include 10q24.1-24.2 and 12p12.3-13.2 in Line2-T500, and
amplification was found at 5q11.2 in Line3-T200 (Table 1).
Although most sites of changes were different between Line2-
T500 and Line3-T200, some commonly involved regions were
identified such as 5q11.2, 11q12.1-q14.3 and 13q33.3-qter. The
most prominent was the narrow amplification in 5q11.2 in Line3-
T200 (Figure 2) and present as a borderline gain in Line2-T500
(Table 1). Increased copy number involving 11q12.1-q14.3 was
detected as a gain in Line3-T200 and as a borderline gain in
Line2-T500 (Figure 2). Gain of 13q31.3-qter was observed in
Line2-T500 and the gain in chromosome 13 observed in Line3
was strongly pronounced for the interval 13q33.3-qter in Line3-
T200 cells. Loss involving distal 11q was observed for 11q22.1-
qter in Line2/Line2-T500 (Figure 2).
Copy number imbalances in relation to gene expression
levels in PPP tolerant cell lines
We next asked whether copy number variations between
parental and PPP treated cell lines were reflected at the mRNA
level as up-regulated or down-regulated genes. For this purpose,
expression profiling was carried out for Line2, Line2-T500, Line3
and Line3-T200 using the Affymetrix platform. Relative copy
number variations by array-CGH were identified by direct
comparison of PPP-tolerant cell lines with parental cell lines using
Nexus, and for all involved loci data were subsequently integrated
with expression levels by Nexus. As illustrated in Figure 3, relative
copy number increases were commonly associated with over-
expression and copy number decreases with under-expression.
Copy number imbalances detected in both Line2-T500 and
Line3-T200 included relative gains in 3q, 4q, 10p, 11q and 13 and
relative losses in 1p, 3p, 5p, 7p, 11q, 12p, 16p, 17q and 21q
(Figure 3). Thirty-one genes with corresponding alterations in
mRNA levels were identified including 23 over-expressed genes
within 3q26.33-q27.1, 10p14, 11p11.2-p11.12, 11q11-q14.3,
13q12.3-q13.2, 13q13.3-q21.1 and 13q21.2 and 8 under-ex-
pressed genes within 12p13.33-p13.31 and 17q24.3-q25.3
(Table 2).
Commonly dysregulated genes in PPP tolerant cell lines
Comparison of expression profiles in PPP tolerant and parental
Line2 and Line 3 cells revealed many dysregulated genes, in
addition to those with concomitant copy number alterations. Two
different sets of criteria were applied for selection. Altogether 561
genes were commonly dysregulated in both lines showing at least
2-fold difference in expression level between tolerant and parental
cell lines. The 286 up-regulated and 275 down-regulated genes are
detailed in Table S4 (Gene list U). Using the more stringent
criteria (detailed in material and methods) from 3,440 informative
transcripts we identified 78 up-regulated and 115 down-regulated
genes (gene list H) that were common to Line2-T500 and Line3-
T200 (Figure 4; Table S5).
A functional annotation of gene lists U and H is detailed in
Tables S6 and S7. From gene list U up-regulated genes were
identified in the categories cell death, down-regulated genes in cell
death, positive regulation of cellular process, cell differentiation,
regulation of programmed cell death, positive regulation of
metabolic process, regulation of cell differentiation, positive
regulation of developmental processes and response to wounding
(Table S6). Genes within the category of cell death were detected
from both list U and H (Table 3). Among these may be noted up-
regulation of Kiaa0367, PTEN, MAPK, BCL2, BCLAF1, CASP1 and
TNFRF19, and down-regulation of EMP1, SOCS3, NAIP, STK17A,
PRKCA, ALDH1A, CLU, PHLDA1, PMAP, TNFRSF1A, ATG5 and
ANXA1. Among these, MAPK, BCL2, SOCS3, ALDH1A and ANXA1
were validated as described below.
Validation of identified genes by siRNA treatment
To confirm the results of the comparative expression analysis
and test the results in a wider range of cell lines, siRNA was used
to alter the gene expression and the effect of PPP on cell viability
was then measured. The tested hypothesis in this experiment was
that the upregulated genes in the tolerant cell lines contribute to
the PPP resistance and therefore suppressing them would increase
sensitivity to PPP. Reciprocally, we designed an experiment in the
parental cell lines and other cancer cell lines by inhibiting genes
from the downregulated group. If downregulation contributes to
PPP resistance, this experiment would validate the gene identifi-
cation process. We used two different approaches in building the
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measured effect on expression, with the top four genes from the up
and downregulated lists from Supplemental Table S4, were
chosen. The second, biased, approach identified five genes from
Table 3 that we believe to have a clear connection with IGF-1R
signaling or with drug resistance. Altogether, six genes that were
identified as downregulated in PPP tolerant cell lines and seven
genes that were identified as upregulated in PPP tolerant cell lines
were chosen for this analysis. The six downregulated genes
included the top four downregulated identifiable genes ALDH1A3
(an aldehyde dehydrogenase involved alcohol and lipid metabo-
lism), ANXA1 (annexin A1, a Ca2+ dependent phospholipase
involved in inflammatory modulation), TLR4 (toll like receptor 4
involved in pathogen recognition in innate immunity) and SPIN3
(spindlin family member 3), plus SOCS3 (suppressor of cytokine
signaling 3) as it is known to interact with IGF-1R, and RAB5A as
it is a member of the Ras oncogene family and so both had
potential direct connections with IGF-1R downstream signaling.
The four most upregulated genes were: COX6A1 (a cytochrome
oxidase involved in the mitochondrial respiratory chain), LGALS2
(a soluble galactoside binding lectin), NFIX (a transcription factor)
and ME1 (malic enzyme 1). In addition, we included in our library
BCL2 as it is involved in negative regulation of apoptosis, MAPK
(ERK2) as it is involved in IGF-1R downstream signaling and
TAP2, a member of the ATP binding cassette (ABC) transporter
family involved in multi-drug resistance.
The genes downregulated in PPP tolerant cell lines were siRNA
silenced in non-tolerant cells Line2, Line3, the melanoma cell line
BE and breast cancer cell line MCF7, all known to express IGF-
1R and to be responsive to PPP [8]. Following transfection with a
non-targeting siRNA control, 500 nM PPP treatment for 48 h
caused cell viability of the parental cell lines Line2 and Line3 to
decrease by 45% and 55%, BE and MCF7 by 34% and 40%,
respectively whereas, as expected, a limited decrease of only 10%
was observed with Line2-T500 and Line3-T200 (Table 4). The
siRNA treatment alone had no significant effect on cell viability.
Downregulation of the top two downregulated genes ALDH1A3
and ANXA1 caused a significant increase in resistance to PPP in all
non-tolerant cell lines including the two parental cell lines. In
addition, treatment with siRNA against TLR4, SPIN3, SOCS3 and
RAB5A increased PPP resistance significantly in at least two of the
four tested cell lines for each gene. Of these, at least one of the
parental cells showed increased resistance with the exception of
SOCS3 for which Line2 and Line3 showed no change however the
other cell lines included, BE and MCF7 both showed significant
increased tolerance (Table 4).
The genes upregulated in PPP resistant cell lines were siRNA
silenced in the cells Line2-T500 and Line3-T200 to determine if a
PPP re-sensitization could be achieved. As an alternative
experimental model, the same genes were silenced in the BE
and MCF7 cells to see if this could increase sensitivity to PPP in
non-resistant cell lines. Treatment of the tolerant cell lines Line2-
T500 and Line3-T200 with siRNA against the upregulated genes
decreased PPP tolerance except for the striking exception of TAP2,
the ABC transporter which is part of the multidrug resistant family
of membrane channels. For TAP2, no significant change was seen
with Line2-T500 however an increase in tolerance was observed
for Line3-T500 which could be explained with its tolerance to a
lower level of PPP. The same pattern was mirrored in the siRNA
treatment of BE and MCF7 against the upregulated genes. A
significant sensitization to PPP was observed in the majority of
cases again, except for TAP2 where MCF7 showed increased
tolerance to PPP and BE showed no significant change (Table 4).
Taken together, the results from this experiment demonstrated a
clear decrease in PPP sensitivity after silencing the downregulated
genes and a clear increase in PPP sensitivity after silencing of the
upregulated genes.
To produce a more complete picture of the effect of these genes
on sensitivity to PPP, siRNA transfected Line2 and Line2-T500
Figure 1. Gains and amplifications involving 8q24.21 and verification of array-CGH results by FISH for the MYC locus. (A) FISH analysis
using a Spectrum Orange labelled BAC clone covering the MYC locus. Line2 cells in metaphase show red signals on 4 individual chromosomes as well
as 4 signals in interphase. In interphase nuclei of Line3-T200 cells single individual red spots are observed together with clusters of more than 10
signals suggesting a homogeneously staining region. (B) Array-CGH profiles for chromosome 8 in parental and PPP tolerant cells. Parental and PPP
tolerant cells show gain of 8q24.13-qter in Line2, narrow amplification of 8q24.21 in Line3. (C) The heatmap illustrates the common regions of gain/
amplification including the MYC and PVT1 loci, with gain indicated in light blue and amplifications marked in dark blue. The first column is the name
of clones in the BAC array.
doi:10.1371/journal.pone.0014757.g001
Table 1. Copy number abnormalities observed by array-CGH
in PPP tolerant cell lines only.
Chr Line2-T500 Line3-T200
Losses
3 - 3p12.3-13
5 5p14.3-pter -
6 6p21.31-qter -
7 - 7q35
9 9p11.3-q12 -
10 10q24.1-q24.2 hz -
11 - 11q21-22.1; q22.1-qter
12 12p13.31-ter; p12.3-13.2 hz -
16 - 16q23.3-qter
17 - 17q23.2
21 21q11.2-22.3 -
Gains
1 - 1q21.1-25.3; q32.1-3; q43-qter
3 - 3q27.3-qter
4 - 4p15.2-pter
5 (5q11.2) 5p15.1-pter; p13.3-q11.2/q11.2
8 - 8q24.22; q24.3
10 10p12.32-pter; q22.2-23.2 -
11 (11p11.12-q14.3) 11p11.12-12; q12.1-21
12 12p12.1-12.3 -
13 13q31.3-qter 13q33.3-qter Pr.
17 - 17q11.2; q12
18 18q21.2-21.31; q22.3-ter 18q12.1
20 20q13.2-13.31 -
22 - 22q12.3; q13.32-q13.33
Bold indicates amplification; Homozygous deletions hz are marked in bold and
italic.
Borderline alterations are given within paranthesis; "Pr" indicates Pronounced
gain.
doi:10.1371/journal.pone.0014757.t001
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shown in Figure 5 treatment of Line2 with siRNA for two genes
detected as downregulated in resistant cell lines, ALDH1A3 and
ANXA1, demonstrated increased resistance following downregula-
tion and incubation with PPP concentrations up to 1 mM.
Significantly increased resistance was detected at 0.05, 0.5 and 1
mM PPP treatment but not at 2.5 mM PPP for either gene. This
confirms the initial siRNA studies and demonstrates a role in
resistance of PPP at a range of concentrations. As shown in Figure 5,
treatment of Line2-T500 with siRNA for two genes detected as
upregulated in resistance cell lines, COX6A1 and NFIX,d e m o n s t r a t -
ed decreased resistance following downregulation and incubation
withPPPatconcentrationsupto1 mM,withnodifferenceseenat2.5
mM. These differences were significant for both genes at 0.5 and 1
mM PPP and again confirm and expand on the initial siRNA studies.
To confirm that the siRNA was decreasing expression of the
relevant genes in the control and resistant cell lines, Line2 and
Line2-T500 were transfected on a larger scale, the RNA extracted
and reverse transcribed into cDNA. This enabled qRT-PCR
measurement of the mRNA level to compare untreated with
siRNA treated and to confirm that the siRNA is functional. qRT-
PCR products were separated by agarose gel electrophoresis to
confirm that they migrated at the expected size and melting curve
analysis confirmed that all amplification products from a primer
pair had the same melting point. Of the downregulated genes, 4
out of 6 showed decreased mRNA expression with siRNA
treatment; ALDH1A3, ANXA1, TLR4 and RAB5A (Table S1). Of
the remaining two, SPIN3 and SOCS3, no conclusive results were
achieved, despite adequate amplification of GAPDH in these
samples, suggesting a problem with primer design. Of the
upregulated genes, 5 out of 7 showed siRNA treatment decreased
mRNA levels; COX6A1, NFIX, ME1, MAPK and TAP2 (Table S1).
No conclusive results were achieved with the remaining two genes,
LGALS2 and BCL2, due to primer design and inadequate amount
of sample, respectively. This demonstrates that the siRNA was
specifically decreasing expression of the relevant genes in all cases
where the PCR assay worked.
Global hypomethylation in PPP tolerant cell lines
Genome-wide methylation at CCGG sites were investigated by
LUMA in parental Line2, Line3 and their derivatives Line2-T500
and Line3T200. We observed significant hypomethylation in
Figure 2. Array-CGH profiles of copy number alterations. Amplification of 5q11.2 in Line3-T200 cells (top) and chromosome 11 copy number
alterations in all lines (bottom). Gain of 11q12.1-q14.3 is identified as a common alteration in Line2-T500 and Line3-T200 cells as compared to Line2
and Line3 cells. For Line2 and Line2-T500 the threshold +0.2 is used to illustrate the border-line gain of 11p11.2-q14.3. Copy number loss of distal 11q
is present in Line3-T200 and in Line2 and Line2-T500. Candidate genes with common over-expression in the region of gain are shown below the
plots. The array-CGH plots of chromosome 5 show alterations outside the thresholds of +0.25 for gain and +1.0 for amplification, as well as borderline
alterations at the +0.25 threshold. The alterations were scored as borderline gain of 5pter-q15 in Line3, and in Line 3-T200 as gain of 5p15.1-pter and
p13.3-q11.2 with borderline gain of p13.3-p15.1 and amplification of q11.2.
doi:10.1371/journal.pone.0014757.g002
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PLoS ONE | www.plosone.org 9 March 2011 | Volume 6 | Issue 3 | e14757Line2-T500 following PPP treatment (p=0.04, Figure 6). In Line2
cells, a similar trend of hypomethylation was observed after
treatment, however the difference did not reach statistical
significance. This trend of hypomethylation was reversed in
Line2-T500 (without adding treatment) but retained in Line2-
T500 after treatment with 500 nM PPP. There was no difference in
DNA methylation between parental Line3 and tolerant lines (data
are not shown). The dose of PPP used in the methylation analysis
was based on our previous results which showed that parental cell
Line2 and Line3 responded to PPP treatment with IC50 values of
around 0.05 and 0.1 mM, respectively [7], and similar toxicity of
PPP for parental cells was also observed in the current study
(Figure 6). As treatment of parental cells with high dose of 1000 nM
PPPwasnot possible, itcannot be determined whether the observed
hypomethylation was related to the acquired tolerance or if it was
merely a result of the high PPP dose during treatment.
Figure 3. Comparison of copy number imbalances with corresponding gene expression levels. Comparison of relative copy number
imbalances between tolerant and parental cells detected in Line2-T500 (top), Line3-T200 (middle), and commonly for Line2-T500 and Line3-T200
(bottom), with corresponding gene expression levels by Affymetrix. Each vertical line represents one abnormality in one sample. In each panel the
upper plots for array-CGH data show relative copy number gains (green) and losses (red) from 1pter to Yqter. The lower plots show genes with
increased (blue) or decreased (purple) expression at loci with altered gene dose in Line2 and Line3.
doi:10.1371/journal.pone.0014757.g003
Table 2. Commonly dysregulated genes in regions of relative copy number alterations in PPP tolerant Line2-T500 and Line3-T200
cells (data by Nexus analyses).
Gene symbol Location Locus
Gene name Chr. start-end (Mb) Link ID
Upregulated genes within regions of relative copy number gain
FXR1 fragile X mental retardation, autosomal homolog 1 3 182.1–182.3 8087
CUGBP2 CUG triplet repeat, RNA binding protein 2 10 11.1–11.5 10659
ACP2 acid phosphatase 2, lysosomal 11 42.2–42.3 53
CUGBP1 CUG triplet repeat, RNA binding protein 1 11 47.4–47.6 10658
FNBP4 formin binding protein 4 11 47.7–47.8 23360
PATL1 protein associated with topoisomerase II homolog 1 11 59.1–59.2 219988
NAT11 N-acetyltransferase 11 (GCN5-related, putative) 11 63.4–63.5 79829
GPR137 G protein-coupled receptor 137 11 63.8–63.9 56834
ATG2A ATG2 autophagy related 2 homolog A 11 64.4–64.5 23130
PPP2R5B protein phosphatase 2, regulatory subunit B’, 11 64.4–64.5 5526
EHBP1L1 EH domain binding protein 1-like 1 11 65.1–65.2 254102
ADRBK1 adrenergic, beta, receptor kinase 1 11 66.7–66.9 156
RAD9A RAD9 homolog A 11 66.9–67.0 5883
CABP4 calcium binding protein 4 11 66.9–67.0 57010
ACY3 aspartoacylase 3 11 67.1–67.2 91703
CTTN Cortactin 11 66.9–67.0 2017
C11orf30 chromosome 11 open reading frame 30 11 75.8–76.0 56946
RAB30 RAB30, member RAS oncogene family 11 82.3–82.5 27314
TMEM126B transmembrane protein 126B 11 85.0–85.1 55863
PICALM phosphatidylinositol binding clathrin assembly protein 11 85.3–85.5 8301
NEK3 NIMA (never in mitosis gene a)-related kinase 3 13 51.6–51.7 4752
UBL3 ubiquitin-like 3 13 29.2–29.4 5412
TDRD3 tudor domain containing 3 13 59.8–60.1 81550
Downregulated genes within regions of relative copy number decrease
RAD52 RAD52 homolog 12 0.8–1.0 5893
FBXL14 F-box and leucine-rich repeat protein 14 12 1.5–1.6 144699
CACNA2D4 calcium channel, voltage-dependent, alpha 2/delta subunit 4 12 1.7–1.9 93589
ITFG2 integrin alpha FG-GAP repeat containing 2 12 2.7–2.9 55846
LRRC23 leucine rich repeat containing 23 12 6.8–6.9 10233
H3F3B H3 histone, family 3B 17 71.2–71.3 3021
SOCS3 suppressor of cytokine signaling 3 17 73.8–73.9 9021
RNF213 ring finger protein 213 17 75.9–76.0 57674
doi:10.1371/journal.pone.0014757.t002
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PLoS ONE | www.plosone.org 11 March 2011 | Volume 6 | Issue 3 | e14757Figure 4. Heat maps and hierarchical clustering of genes in gene list H. The heat maps show (A) upregulated and (B) downregulated genes
in PPP tolerant (Line2-T500 and Line3-T200) cells as compared to parental Line2 and Line3 cells. Relative expression levels are indicated according to
the colour scale and further gene information is given in Table S5.
doi:10.1371/journal.pone.0014757.g004
Table 3. Genes dysregulated in PPP tolerant Line2-T500 and Line3-T200 cells in GO category 0008219 cell death (from gene list U).
Gene symbol Gene name Location Line2-T500 Line3-T200
Up-regulated
VDAC-1 voltage-dependent anion channel 1 5q31 up up
KIaa0367 KIAA0367 9p21.13 up up
CECR2 cat eye syndrome chromosome region, candidate 2 22q11.2 up up
PTEN phosphatase and tensin homolog 10q22.3 up up
MAPK* Mitogen-activated protein kinase 1 22q11.2 up up
BCL2* B-cell CLL/lymphoma 2 18q21.33 up up
BCLAF1 BCL2-associated transcription factor 1 6q22-23 up up
CASP1 Caspase-1 11q23 up up
HRK harakiri, BCL2 interacting protein 12q24.22 up up
PHF17 PHD finger protein 17 4q26-q27 up up
FKSG2 Apoptosis inhibitor 8p11.2 up up
EIF5A Eukaryotic translation initiation factor 5A 17p13-12 up up
TNFRSF19 tumor necrosis factor receptor superfamily, member 19 13q12.11-12.3 up up
ADORA1 Adenosine A1 receptor 1q32.1 up up
Lgals1 Lectin, Galactoside-binding, soluble, 1 (Galectin 1) 22q13.1 up up
PSEN2 Presenilin 2 1q31-42 up up
CRYAB crystallin, alpha B 11q22.3-23.1 up up
CFLAR CASH, CASP8 and FADD-like apoptosis regulator 2q33-34 up up
Down-regulated
EMP1 Epithelial membrane protein 12p12.3 down down
SOCS3* Suppressor of cytokine signaling 3 17q25.3 down down
NAIP NLR family, apoptosis inhibitory protein 5q13.1 down down
ERCC-6 DNA excision repair protein ERCC-6, CDNA FLJ13497 fis 10q11.23 down down
STK17A Serine/Threonine kinase 17A (apoptosis-inducing) 7p12-p14 down down
PRKCA Protein kinase C, alpha 17q22 down down
PMAP phorbol-12-myristate-13-acetate-induced protein 1 18q21.32 down down
BCLAF1 BCL2-associated transcription factor 1 6q22-23 down down
EFHC1 Hypothetical protien fli10466 6p12.3 down down
CLU Clusterin 8p21-12 down down
ALDH1A3* Aldehyde dehydrogenase 1 family, member 3 15q26.3 down down
ABPP Amyloid beta (A4) protein 21q21.2 down down
MCL-1 myeloid cell leukemia sequence 1 (bcl2-related) 1q21 down down
CTNNAL1 catenin (cadherin-associated protein), alpha-like 1 9q31.2 down down
PHLDA1 Pleckstrin homology-like domain, family A, member 1 17q22-23 down down
KRT-20 Keratin-20 17q21.2 down down
PAWR PRKC apoptosis WT1 regulator protein, CDNA FLJ14942 fis 12q21 down down
ANXA1* annexin A1 9p12-q21.2 down down
TRIM35 Tripartite motif-containing protein 35, IMAGE:4052341 8p21.2 down down
TNFRSF1A tumor necrosis factor receptor superfamily, member 1A 12p13.2 down down
SH3KBP1 SH3-domain kinase binding protein 1 Xp22.1-21 down down
ATG5 ATG5 autophagy related 5 homolog (S. cerevisiae) 6q21 down down
*indicates genes validated by siRNA.
doi:10.1371/journal.pone.0014757.t003
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Drug resistance may occur as an acquired phenotype after long-
term treatment. It may also be characteristic of the primary tumor,
either as a feature at initial diagnosis or following selection of
tolerant tumor cells. Given the techniques applied, the DNA copy
number abnormalities observed in our study are expected to be
representative for the majority of cells in each line studied. In this
study we focus our attention mainly on molecular changes related
to PPP tolerance. However, some striking aberrations common to
parental and tolerant cells deserve some discussion as they may
have a permissive role in resistance development. The oncogenes
MYC and PVT1 in 8q24.1 were amplified or gained in all lines
(Figure 1). PVT1 is a c-Myc activator implicated in murine tumors
and in the same pathways as c-Myc [32] and c-Myc is a
transcriptional regulator affecting cellular processes such as
growth, metabolism, division and apoptosis. In animal models,
lack of IGF-1R did not prevent tumor formation or progression
when c-myc was induced [33] and ectopic expression of c-Myc
could override the suppressive effects of p16, p21 and p27 to
promote cell cycle progression [34]. In this context, the
homozygous loss in 9p21.3 observed in Line2/Line2-T500 cells
is also noteworthy as it includes CDKN2A encoding the cell cycle
regulator p16 and p14ARF. Gil et al. demonstrated that c-Myc can
promote cell cycle progression regardless of the presence of growth
factors [35]. In addition, it has been shown that CDKN2A loss can
contribute towards resistance to targeted therapy in acute
lymphoblastic leukemia induced by BCR-ABL translocation [36].
It is known that PPP can be non-enzymatically converted to the
microtubule inhibitor podophyllotoxin (PPT) [37] with a PPP:PPT
steady state equilibrium of 97.5:2.5%. This means that up to 2.5%
of PPP converts to PPT. Consistently we have detected small
amounts of PPT in culture media incubated with PPP but have not
observed any detectable levels of PPT in blood samples from
animals (unpublished data) treated with high doses of PPP [10]. In
agreement with possible PPT exposure of PPP treated cells
(#12.5 nM in Line2-T500; #5 nM in Line 3-T200) we observed
commonly altered expression of tubulin or microtubule associated
genes in Line2-T500 and Line3-T200 cells. These included over-
expression of MARK1 (9.3 fold change) and TUBA4A (4.4 fold) and
under-expression of EML5 (0.19 fold) and MICAL2 (0.26 fold).
In this study we combined two separate analysis methods array-
CGH which detects DNA copy number alterations with
expression array which provides information at the transcriptional
level. We identified genes that were altered in both studies and
which are therefore strong candidates for contributing to PPP
tolerance. Amplification and gain involving 5q11.2, gain of 11p12
and 11q12.1-q14.3 and gain of 13q33.3-qter were found as
commonly acquired aberrations in Line2-T500 and Line3-T200.
Among these the narrow amplification of 5q11.2 in Line3-T200 is
the most prominent alteration, but was not paralleled with
increased expression for informative genes in the amplified region.
However, up-regulation was observed for genes in the gained
11p12 region including ACP2, CUGBP1 and FNBP4 and in the
gained 11q12.1-q14.3 interval for ATG2A, CABP3, NAALAD2,
TncRNA, CTTN, RAB30 and EHBP1. In addition, under-
expression of genes from the distal lost 11q region was observed
for UBASH3B, ZC3H12C, RICS and ETS1. The gain of 13q33.3-
qter was paralleled by up-regulation of TMCO3 and KDELC1.
Considering expression profiles, the most pronounced alteration
identified was the cytochrome c oxidase subunit 6A1 (COX 6A1)o n
Table 4. Validation of identified genes by siRNA treatment.
Downregulated genes
Negative ALDH1A3 ANXA1 TLR4 SPIN3 SOCS3 RAB5A
Line2 Mean 0.555 0.718 q* 0.746 q*0 . 6 2 8 q* 0.582 NS 0.549 NS 0.661 q
SEM 0.0015 0.0163 0.0273 0.0080 0.0295 0.0033 0.0449
Line3 Mean 0.494 0.529 q* 0.601 q*0 . 5 9 6 q 0.568 q* 0.508 NS 0.659 q*
SEM 0.0047 0.0111 0.0284 0.0498 0.0087 0.0060 0.0316
BE Mean 0.662 0.732 q* 0.861 q* 0.701 NS 0.876 q* 0.698 q* 0.799 q*
SEM 0.0073 0.0047 0.0143 0.0383 0.0208 0.0058 0.0407
MCF7 Mean 0.600 0.768 q* 0.745 q*0 . 6 9 6 q* 0.674 NS 0.712 q* 0.673 q
SEM 0.0288 0.0209 0.0192 0.0195 0.0297 0.0105 0.0232
Upregulated genes Negative COX6A1 LGALS2 NFIX ME1 BCL2 MAPK TAP2
Line2-T500 Mean 0,895 0.736 Q* 0.566 Q*0 . 7 2 3 Q* 0.706 Q* 0.502 Q* 0.740 Q* 0.870 NS
SEM 0.0412 0.0078 0.0021 0.0164 0.0052 0.0047 0.0072 0.0349
Line3-T200 Mean 0.901 0.840 Q 0.768 Q*0 . 6 6 7 Q* 0.537 Q* 0.811 Q* 0.538 Q* 0.967 q*
SEM 0.0159 0.0197 0.0341 0.0171 0.0155 0.0195 0.0167 0.0102
BE Mean 0.662 0.539 Q* 0.555 Q*0 . 4 8 5 Q* 0.461 Q* 0.489 Q* 0.426 Q* 0.695 NS
SEM 0.0073 0.0153 0.0161 0.0070 0.0049 0.0028 0.0120 0.0175
MCF7 Mean 0.600 0.354 Q* 0.427 Q*0 . 5 3 7 Q 0.483 Q* 0.347 Q* 0.548 NS 0.928 q*
SEM 0.0288 0.0123 0.0567 0.0108 0.0080 0.0175 0.0164 0.0461
The PPP sensitivity ratio was calculated as fluorescence from wells treated with PPP to those treated without PPP.
Statistical significance was calculated using the T test compared to the wells treated with negative control siRNA.
Q = Trend in decreased tolerance to PPP, p,0.1; Q* = Significant decreased tolerance to PPP, p,0.05.
q = Trend in increased tolerance to PPP, p,0.1; q* = Significant increased tolerance to PPP, p,0.05.
NS = No statistically significant change.
doi:10.1371/journal.pone.0014
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induced apoptosis [38]. The increase in COX6A1 expression was
confirmed to contribute to PPP resistance after suppression of
expression by siRNA in the tolerant celllines and it was demonstrated
that this effect was not limited to the paired tolerant cell lines.
Furthermore, genes within the functional category cell death were
over-represented among both up and down regulated genes.
IGF-1R is a cell surface receptor tyrosine kinase (RTK) that is
substantially expressed in malignant tissues and plays a crucial role
in growth and survival of cancer cells but is not absolutely required
for normal cell growth [39]. Targeting the IGF-1R is today an
attractive concept in oncology and many pharmaceutical compa-
nies are developing anti-IGF-1R agents, of which several are now
in clinical trials. A substantial part of the anti-neoplastic effects of
PPP have been proposed to occur through the IGF-1R. PPP was
not only reported to attenuate IGF-1R activity but also to
downregulate the receptor [17]. This effect may be important for
its strong anti-tumor efficacy and is consistent with the current
concept that inhibition of IGF-1R phosphorylation only decreases
proliferation of tumor cells whereas in order to promote massive
apoptosis and tumor regression the receptor needs to be
downregulated.
Insensitivity to drug-induced apoptosis plays an important role
in acquired anticancer drug resistance. Different strategies applied
to inhibit IGF-1R expression or function have resulted in blocking
tumor growth and metastasis and have enhanced sensitivity to
cytostatic drugs and irradiation [39,40-41]. Therefore one could
expect that in the case of PPP, an acquired resistance mechanism
would only barely evolve. The balance between the pro-survival
and pro-apoptotic factors encoded by the genetic alterations
associated with the tolerant phenotype in the Line2-T500 and
Line3-T200 must have allowed the establishment of limited
resistance to PPP over the 80 week period.
We found significant hypomethylation after PPP treatment in
Line2-T500 cells and there was also a trend of hypomethylation in
Line2 cells. Based on experiments performed it could not be
Figure 5. PPP sensitivity curves following siRNA treatment. (A) Line2 cells were treated with siRNA for the downregulated genes ALDH1A3 or
ANXA1, and (B) PPP tolerant Line2-T500 cells were treated with siRNA for the upregulated genes COX6A1 or NFIX. Cell lines transfected with siRNA
were incubated with 0, 0.05, 0.5, 1 and 2.5 mM PPP for 48 hours and cell viability assessed using alamarBlue as described in the materials and
methods. Cell numbers were interpolated from a standard curve and plotted relative to untreated cells. Statistical significance, p#0.05, as calculated
using a two tailed T test is indicated by *.
doi:10.1371/journal.pone.0014757.g005
Mechanisms of PPP Tolerence
PLoS ONE | www.plosone.org 14 March 2011 | Volume 6 | Issue 3 | e14757concluded whether the hypomethylation was related to the
acquired PPP tolerance or if they resulted from the high dose of
PPP. Hypermethylation of CpG islands at tumor suppressor genes
switches off these genes whereas global hypomethylation leads to
genomic instability and activation of oncogenes. Considering the
limited changes in the gene copy number in tolerant versus
parental cell lines it is possible that epigenetic activation of
oncogenes is able to substitute for the IGF-1R signaling to
contribute to the development of PPP tolerance. This factor,
especially in relation to the inhibitory effect of PPP on IGF-1R
should be investigated in more detail.
DNA copy number imbalances between parental and PPP
treated cells were limited suggesting that PPP treatment does not
induce high level amplification of drug resistance genes.
Abnormalities related to PPP tolerance observed in chromosomal
regions 3q26, 10p14, 11p11, 11q11, 12p13, 13q12, 13q13 and
17q24 correlated with altered gene expression. This correlation
increases the probability that genes in these regions were subjected
to selective pressure to contribute to drug tolerance. An additional
set of commonly dysregulated genes were identified without
concomitant alteration in DNA copy number. Genes functionally
related to cell death were significantly dysregulated.
The mechanism behind acquired PPP resistance is clearly
very complex, with a large number of dysregulated genes. For
this reason it is impossible to assess the contribution of each
gene to the resistant phenotype. Nevertheless, by using a small
siRNA library we have validated the process used to identify
dysregulated genes. The siRNA experiments clearly demon-
strated that suppression of expression of the top identifiable
down and upregulated genes had clear effects on sensitivity to
PPP matching their alteration in expression in the tolerant cell
lines. These effects were not limited to the cell lines in the
study but extended to the two other cancer cell lines tested, BE
and MCF7. The four additional genes tested that were chosen
from the up and downregulated lists due to connections with
IGF-1R function (SOCS3, RAB5A BCL2 and MAPK)a l s o
showed effects appropriate to their alteration in the tolerant
cell lines.
In summary, in the present study we used an in vitro approach to
identify the genetic changes induced by prolonged exposure to an
IGF-1R inhibitor and the possible mechanisms of acquired
resistance to such treatment. By analysing the DNA copy number
alterations in combination with transcripts expression array we
could identify the genes that are strong candidates for contributing
to PPP tolerance. Moreover, we could validate the identification
process by silencing them both in the resistant cell lines model and
in naive cell lines.
Supporting Information
Figure S1 Representative SKY karyotypes of parental Line2
and Line3 cells. Each chromosome is shown in SKY painting
colors (left) and in SKY classification pseudo-colors (right).
Chromosome numbers are indicated below, as well as to the
right of derivatives composed of two or more different chromo-
somes.
Found at: doi:10.1371/journal.pone.0014757.s001 (2.44 MB TIF)
Figure S2 Schematic illustrations of copy number alterations
detected by metaphase CGH in parental and tolerant cells. Copy
number alterations detected by metaphase CGH in parental Line2
and Line3 cells (C) as compared to PPP tolerant derivatives at
different levels of PPP in Line2 (40, 100, 300, 400 and 500 nM
PPP) and Line3 (40 and 100 and 200 nM PPP at two different
time-points) cells. Alterations are indicated along the chromosome
Figure 6. Global hypomethylation after PPP treatment of Line2 cells. Methylation at CCGG sites measured by LUMA in PPP sensitive Line2
and tolerantLine2-T500 cells. The Y-axis shows the HpaII/MspI ratio, which correlates inversely to DNA methylation levels. Line2 cells cultured in PPP
free media were short-term treated for 24 h with or without 500 nM PPP. Line2-T500 cells cultured in 500 nM PPP were similarly treated for 24 h by
adding 500 nM PPP (total concentration 1000 nM). Peak heights were plotted with error bars 6 SD. P-values were calculated using the t-test, n.s. =
not statistically significant.
doi:10.1371/journal.pone.0014757.g006
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and in bold for amplifications.
Found at: doi:10.1371/journal.pone.0014757.s002 (0.29 MB TIF)
Table S1 Results and primer details for qRT-PCR analyses of
siRNA.
Found at: doi:10.1371/journal.pone.0014757.s003 (0.02 MB
PDF)
Table S2 Copy number abnormalities by array-CGH in
parental and PPP tolerant Line2, Line3 cells.
Found at: doi:10.1371/journal.pone.0014757.s004 (0.02 MB
PDF)
Table S3 Homozygous losses and narrow narrow amplifications
detected.
Found at: doi:10.1371/journal.pone.0014757.s005 (0.02 MB
PDF)
Table S4 Gene list U, commonly up-regulated or down-
regulated genes in Line2-T500 and Line3-T200 cells (.2-fold
difference between parental and PPP tolerant cells).
Found at: doi:10.1371/journal.pone.0014757.s006 (0.15 MB
PDF)
Table S5 Gene list H, up and down-regulated genes in PPP
tolerant Line2-T500 and line3-T200 cells (including genes with
.2-fold difference vs parental cells).
Found at: doi:10.1371/journal.pone.0014757.s007 (0.03 MB
PDF)
Table S6 Ontological categories generated from common up-
regulated and down-regulated genes in PPP tolerant Line2-T500
and Line3-T200 cells (by DAVID, from gene list U).
Found at: doi:10.1371/journal.pone.0014757.s008 (0.04 MB
PDF)
Table S7 Ontological categories generated from common up-
and down-regulated genes in PPP tolerant Line2-T500 and Line3-
T200 cells (by DAVID, from gene list H).
Found at: doi:10.1371/journal.pone.0014757.s009 (0.01 MB
PDF)
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